This week's episode covers a new AHA scientific statement on caffeine safety and cardiovascular benefit, pharmacist guidance for protecting asthma, COPD, and allergy patients during wildfire smoke events, and regulatory updates in obstructive sleep apnea and ROS1-positive lung cancer.

Data show adalimumab biosimilars can replace brand-name treatment with minimal gaps, high persistence, and sharply lower drug costs for patients and plans.

A year-long trial suggests the tuberculosis vaccine may retrain immune cells in the brain and shift Alzheimer-related biomarkers in older adults without existing pathology.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses where VER-01 could fit within chronic pain management and why advances in standardized cannabinoid therapies may represent a pivotal moment for the future of evidence-based cannabis-derived medicines.

Jordan Hill, PharmD, BCOP, discusses the expanded first-line role of sacituzumab govitecan in metastatic triple-negative breast cancer and how PD-L1 status informs its use alone or with pembrolizumab.

Federal guidelines and clinical evidence suggest that doubling or even tripling up on shots is not only safe but is also a best practice.